Education
About Us
Working with TipRanks
Follow Us
Laboratorios Farmaceuticos Rovi (ES:ROVI)
:ROVI
RESEARCH TOOLSreports
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.99Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -6.71%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging year for Rovi with significant declines in operating revenue, CDMO sales, EBITDA, and net profit, primarily due to decreased COVID-19 vaccine manufacturing revenues. However, there are positive aspects such as growth in the specialty pharma business, particularly with Okedi and Bemiparin, and improvements in ESG ratings. The company is investing in future growth, particularly in the CDMO segment, but faces short-term operational and financial challenges.Company Guidance
In the call, Rovi provided guidance for 2025, expecting operating revenue to decrease by a mid-single-digit percentage compared to 2024. The company highlighted a 7.9% decline in operating revenue to €763.7 million in 2024, primarily due to reduced CDMO sales of €336.2 million, which were impacted by lower revenues from COVID-19 vaccine manufacturing. Despite this, the specialty pharmaceutical business saw a 2% increase in sales to €427.5 million, driven by products like Okedi, which doubled its sales to €28.8 million. Rovi's gross margin improved by 370 basis points to 62.7%, although EBITDA decreased by 15% to €207.4 million, and net profit dropped 20% to €136.9 million. The company also reported a significant reduction in raw material prices for low-molecular-weight heparins, which fell by 54%. Rovi's CapEx in 2024 was €62.2 million, with investments in expanding CDMO capacities and other strategic projects. The company remains optimistic about future growth driven by its specialty pharma area, CDMO business, and ongoing investments in R&D and infrastructure.Specialty Pharma Business Growth
Sales of the specialty pharmaceutical business increased by 2% in 2024, reaching €427.5 million, driven by products like Okedi, Neparvis, and contrast imaging agents.
Okedi Risperidone ISM Performance
Sales of Okedi doubled in 2024, reaching €28.8 million, and it was launched in new markets including Finland, the rest of the Nordic countries, Australia, Taiwan, and the Netherlands.
Bemiparin Sales Increase
Bemiparin international sales grew by 16% with strong contributions from China, Turkey, and Greece, despite an overall slow down in the Heparin franchise.
ESG Improvements
Rovi improved its ESG risk rating to 16.1 from 16.4 in the previous year and was ranked fifth in the world ESG risk ranking among 424 pharmaceutical companies.
Future CDMO Growth Prospects
A new agreement for pre-filled syringes with a global pharmaceutical company is expected to increase CDMO revenue by 20% to 45% over 2023 sales starting in 2027.
---
Laboratorios Farmaceuticos Rovi (ES:ROVI) Earnings, Revenues Date & History
ES:ROVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ES:ROVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | €55.15 | €55.15 | 0.00% |
| Nov 07, 2024 | €75.65 | €65.75 | -13.09% |
| Jul 31, 2024 | €86.20 | €89.00 | +3.25% |
| May 08, 2024 | €81.93 | €80.55 | -1.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Laboratorios Farmaceuticos Rovi (ES:ROVI) report earnings?
Laboratorios Farmaceuticos Rovi (ES:ROVI) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Laboratorios Farmaceuticos Rovi (ES:ROVI) earnings time?
Laboratorios Farmaceuticos Rovi (ES:ROVI) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Laboratorios Farmaceuticos Rovi stock?
The P/E ratio of Laboratorios Farmaceuticos Rovi is N/A.
What is ES:ROVI EPS forecast?
Currently, no data Available
---